Humalog vs

Humalog vs. Novolog: Important Differences and More

What are the major differences between Humulin (HMO) and Novolin (NovoLog)? What are the main advantages and disadvantages?

These questions will help you make your decision on which one to use. You might want to read more about these topics before making your choice.

The following sections explain what each drug does, how it works, its side effects, etc…

1. What do they do exactly?

Humalog is a type of long acting insulin used for diabetes management. It is a single-ingredient medication that must be taken daily or every other day. The active ingredient is called human insulin, which comes from pancreases of diabetics. Humalog’s mechanism of action is similar to that of other types of insulin such as Lantus® and Novolog® (NovoLog).

Humalog works by increasing blood sugar levels so that the body can use stored glucose instead of converting it into fat.

Novolog is a type of long acting insulin used for diabetes management. It is a combination of two different drugs: NovoLog® (Lantus®) and Humulin (HMO). They work together to increase blood sugar levels and lower triglyceride levels. The ingredients are both fast-acting and long-acting insulins.

2. How do they work?

Humalog has a rapid onset and peak with a shorter duration of action. It starts to lower blood sugar within 15 minutes and works for 3 to 5 hours.

NovoLog starts to lower blood sugar within 1 hour and peaks at 2 to 4 hours, but keeps working for 12 hours or longer.

3. What is their history?

Insulins have been used for more than 90 years. In 1922, the first animal insulin was isolated from the pancreas of beef cattle. In the early 1970’s, human insulins became available and have helped save lives of people with diabetes.

Humalog was created in the late 1980’s and became available to the public in 1996.

NovoLog was approved by the FDA in 2006.


Sources & references used in this article:

Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. by P Roach, L Yue, V Arora – Diabetes care, 1999 – Am Diabetes Assoc

Effectiveness of postprandial Humalog in toddlers with diabetes by KS Rutledge, HP Chase, GJ Klingensmith… – Pediatrics, 1997 – Am Acad Pediatrics

Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. by R Renner, A Pfützner, M Trautmann, O Harzer… – Diabetes …, 1999 – Am Diabetes Assoc

The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes by HP Chase, T Lockspeiser, B Peery, M Shepherd… – Diabetes …, 2001 – Am Diabetes Assoc

Pregnancy outcome in type 1 diabetes mellitus treated with insulin lispro (Humalog) by EA Masson, JE Patmore, PD Brash, M Baxter… – Diabetic …, 2003 – Wiley Online Library